{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T13:51:20Z","timestamp":1765893080672,"version":"3.48.0"},"reference-count":29,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T00:00:00Z","timestamp":1663891200000},"content-version":"unspecified","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"crossref","award":["GNT1150996"],"award-info":[{"award-number":["GNT1150996"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1111596\/1173163"],"award-info":[{"award-number":["1111596\/1173163"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032244","name":"Perth Children's Hospital Foundation","doi-asserted-by":"crossref","award":["9722 & 9757"],"award-info":[{"award-number":["9722 & 9757"]}],"id":[{"id":"10.13039\/100032244","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Career Development Fellowship","award":["GNT1111657"],"award-info":[{"award-number":["GNT1111657"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2022,5,15]]},"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Pulmonary exacerbations are associated with increased morbidity and mortality in people with cystic fibrosis (CF). There is no consensus about which outcomes should be evaluated in studies of pulmonary exacerbations or how these outcomes should be measured. Outcomes of importance to people with lived experience of the disease are frequently omitted or inconsistently reported in studies, which limits the value of such studies for informing practice and policy. To better standardise outcome reporting and measurement, we aim to develop a core outcome set for studies of pulmonary exacerbations in people with CF (COS-PEX) and consensus recommendations for measurement of core outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>Preliminary work for development of COS-PEX has been reported, including (1) systematic reviews of outcomes and methods for measurement reported in existing studies of pulmonary exacerbations; (2) workshops with people affected by CF within Australia; and (3) a Bayesian knowledge expert elicitation workshop with health professionals to ascertain outcomes of importance. Here we describe a protocol for the additional stages required for COS-PEX development and consensus methods for measurement of core outcomes. These include (1) an international two-round online Delphi survey and (2) consensus workshops to review and endorse the proposed COS-PEX and to agree with methods for measurement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>National mutual ethics scheme approval has been provided by the Child and Adolescent Health Service Human Research Ethics Committee (RGS 4926). Results will be disseminated via consumer and research networks and peer-reviewed publications. This study is registered with the Core Outcome Measures in Effectiveness Trials database.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2021-056528","type":"journal-article","created":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T00:20:13Z","timestamp":1663978813000},"page":"e056528","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Protocol for establishing a core outcome set for evaluation in studies of pulmonary exacerbations in people with cystic fibrosis"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3197-7493","authenticated-orcid":false,"given":"Charlie","family":"McLeod","sequence":"first","affiliation":[{"name":"Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Perth, Western Australia, Australia"},{"name":"Infectious Diseases Department, Perth Children's Hospital, Nedlands, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5494-5438","authenticated-orcid":false,"given":"Alan Robert","family":"Smyth","sequence":"additional","affiliation":[{"name":"Division of Child Health, Obstetrics and Gynaecology, University of Nottingham, Nottingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitch","family":"Messer","sequence":"additional","affiliation":[{"name":"Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Perth, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre","family":"Schultz","sequence":"additional","affiliation":[{"name":"Wal-Yan Respiratory Research Centre, Telethon Kids Institute, The University of Western Australia, Perth, Western Australia, Australia"},{"name":"Department of Respiratory and Sleep Medicine, Perth Children's Hospital, Nedlands, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie","family":"Wood","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Norman","sequence":"additional","affiliation":[{"name":"School of Public Health, Curtin University, Perth, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher C","family":"Blyth","sequence":"additional","affiliation":[{"name":"Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Perth, Western Australia, Australia"},{"name":"Infectious Diseases Department, Perth Children's Hospital, Nedlands, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Webb","sequence":"additional","affiliation":[{"name":"Intensive Care Unit, St John of God Health Care, West Perth, Western Australia, Australia"},{"name":"School of Population Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoe","family":"Elliott","sequence":"additional","affiliation":[{"name":"Consumer representative, University of Nottingham, Nottingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald","family":"Van Devanter","sequence":"additional","affiliation":[{"name":"Case Western Reserve University School of Medicine, Cleveland, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne L","family":"Stephenson","sequence":"additional","affiliation":[{"name":"Department of Respirology, St Michael's Hospital, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8973-9538","authenticated-orcid":false,"given":"Allison","family":"Tong","sequence":"additional","affiliation":[{"name":"Centre for Kidney Research, The Children's Hospital at Westmead, Sydney, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas L","family":"Snelling","sequence":"additional","affiliation":[{"name":"School of Public Health, The University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,9,23]]},"reference":[{"key":"2025121605490735000_12.9.e056528.1","article-title":"Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis","volume":"7","author":"Hurley","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121605490735000_12.9.e056528.2","first-page":"CD006682","article-title":"Duration of intravenous antibiotic therapy in people with cystic fibrosis","volume":"9","author":"Abbott","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121605490735000_12.9.e056528.3","first-page":"CD002009","article-title":"Once-Daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis","volume":"9","author":"Bhatt","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121605490735000_12.9.e056528.4","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008319.pub3"},{"key":"2025121605490735000_12.9.e056528.5","article-title":"Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis","volume":"11","author":"Waters","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121605490735000_12.9.e056528.6","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002007.pub4"},{"key":"2025121605490735000_12.9.e056528.7","first-page":"CD009530","article-title":"Bronchoscopy-guided antimicrobial therapy for cystic fibrosis","volume":"9","author":"Jain","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121605490735000_12.9.e056528.8","article-title":"Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation","volume":"4","author":"Lord","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121605490735000_12.9.e056528.9","article-title":"Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis","volume":"5","author":"Smith","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121605490735000_12.9.e056528.10","article-title":"Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis","volume":"6","author":"Smith","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121605490735000_12.9.e056528.11","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-15-247"},{"key":"2025121605490735000_12.9.e056528.12","unstructured":"Core Outcome Measures in Effectiveness Trials (COMET) database [Internet], 2020. Available: http:\/\/www.comet-initiative.org\/."},{"key":"2025121605490735000_12.9.e056528.13","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jcf.2020.08.015","article-title":"Outcomes and endpoints reported in studies of pulmonary exacerbations in people with cystic fibrosis: a systematic review","volume":"19","author":"McLeod","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2025121605490735000_12.9.e056528.14","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0354-2020"},{"key":"2025121605490735000_12.9.e056528.15","doi-asserted-by":"crossref","unstructured":"McLeod C , Wood J , Mulrennan S . Preferred health outcome states following treatment for pulmonary exacerbations of cystic fibrosis. J Cys Fib 2021.doi:10.1016\/j.jcf.2021.11.010","DOI":"10.1016\/j.jcf.2021.11.010"},{"key":"2025121605490735000_12.9.e056528.16","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(15)00307-4"},{"key":"2025121605490735000_12.9.e056528.17","unstructured":"Smyth A . The core outcome set Taskforce for CF (COST-CF): core outcome measures in effectiveness trials (COSMIN), 2017. Available: https:\/\/www.comet-initiative.org\/Studies\/Details\/882"},{"key":"2025121605490735000_12.9.e056528.18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002447","article-title":"Core outcome Set-STAndards for development: the COS-STAD recommendations","volume":"14","author":"Kirkham","year":"2017","journal-title":"PLoS Med"},{"key":"2025121605490735000_12.9.e056528.19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002148","article-title":"Core outcome Set-STAndards for reporting: the COS-STAR statement","volume":"13","author":"Kirkham","year":"2016","journal-title":"PLoS Med"},{"key":"2025121605490735000_12.9.e056528.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2017.12.020"},{"key":"2025121605490735000_12.9.e056528.21","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2021-000877"},{"key":"2025121605490735000_12.9.e056528.22","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-017-2128-8"},{"key":"2025121605490735000_12.9.e056528.23","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jclinepi.2020.01.004","article-title":"Controversy and debate series on core outcome sets. paper 1: improving the generalizability and credibility of core outcome sets (COS) by a large and international participation of diverse stakeholders","volume":"125","author":"Chevance","year":"2020","journal-title":"J Clin Epidemiol"},{"key":"2025121605490735000_12.9.e056528.24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000393"},{"key":"2025121605490735000_12.9.e056528.25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135162","article-title":"Evaluation of nine consensus indices in Delphi foresight research and their dependency on Delphi survey characteristics: a simulation study and debate on Delphi design and interpretation","volume":"10","author":"Birko","year":"2015","journal-title":"PLoS One"},{"key":"2025121605490735000_12.9.e056528.26","unstructured":"tool QS , 2021. Available: https:\/\/www.qualtrics.com\/au\/?utm_source=google&utm_medium=ppc&utm_campaign=APJ-ANZ-Brand-Qualtrics-Brand&utm_keyword=qualtrics&MatchType=e&adid=492567885792&utm_content=492567885792&adgroupid=112314781144&campaignid=10690854453&AdGroup=%7BAdGroup%7D&BidMatchType=%7BBidMatchType%7D&Target=&targetid=kwd-350281095527&Device=c&devicemodel=&loc_phsyical_ms=9070544&Placement=&querystring=%7Bquerystring%7D&network=g&adposition=&GCLID=EAIaIQobChMI1cCXpZC07wIVhjMqCh3UvQGHEAAYASAAEgLy9_D_BwE&gclid=EAIaIQobChMI1cCXpZC07wIVhjMqCh3UvQGHEAAYASAAEgLy9_D_BwE"},{"key":"2025121605490735000_12.9.e056528.27","unstructured":"Akl E , Mustafa R , Wiercioch N . Grade Handbook: grade group, 2021. https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html"},{"key":"2025121605490735000_12.9.e056528.28","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-017-2298-4","article-title":"Standardised outcomes in Nephrology-Polycystic kidney disease (SONG-PKD): study protocol for establishing a core outcome set in polycystic kidney disease","volume":"18","author":"Cho","year":"2017","journal-title":"Trials"},{"key":"2025121605490735000_12.9.e056528.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2013.11.013"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-056528","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T13:49:15Z","timestamp":1765892955000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-056528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":29,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9,23]]},"published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1136\/bmjopen-2021-056528"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-056528","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2022,9]]}}}